Insilico Medicine
PulseAugur coverage of Insilico Medicine — every cluster mentioning Insilico Medicine across labs, papers, and developer communities, ranked by signal.
- founded Alex Zhavoronkov 90%
- partners with Takeda Pharmaceutical Company 90%
- uses Chemistry42 90%
- partners with Alex Zhavoronkov 90%
- uses PandaOmics 90%
- developed by rentosertib 90%
- affiliated with Alex Zhavoronkov 70%
- partners with rentosertib 70%
- partners with PandaOmics 70%
- competes with Claude Science 60%
- invested in Takeda Pharmaceutical Company 50%
- affiliated with Chemistry42 50%
- 2026-08-07 product_launch Insilico Medicine is leveraging its AI drug discovery platform, Pharma.AI, by licensing it to other pharmaceutical companies. source
- 2026-07-22 funding Eli Lilly and Company acquired Insilico Medicine for $2.75 billion. source
- 2026-07-15 partnership Insilico Medicine entered into a global strategic partnership with Takeda Pharmaceutical, with a total transaction value of up to $600 million. source
- 2026-06-22 partnership Insilico Medicine and SK Biopharmaceuticals have partnered on an AI-driven drug discovery initiative with a potential value exceeding $2.5 billion. source
- 2026-06-22 partnership Insilico Medicine and SK Biopharmaceuticals Co. have formed a research and development collaboration valued at up to $2.5 billion to discover AI-driven drug candidates for CNS neuroinflammatory diseases. source
- 2026-06-02 funding Eli Lilly and Company acquired drug candidates from Insilico Medicine for $2.75 billion. source
- 2026-06-02 funding Eli Lilly acquired drug candidates from Insilico Medicine for $2.75 billion. source
- 2026-06-02 funding Eli Lilly acquired AI-designed drugs from Insilico Medicine for $2.75 billion. source
- 2026-06-02 funding Eli Lilly acquired drug candidates from Insilico Medicine for $2.75 billion. source
- 2026-06-02 funding Eli Lilly and Company acquired drugs designed by Insilico Medicine for $2.75 billion. source
- 2026-05-27 partnership Insilico Medicine and Human Longevity formed a partnership to develop AI models for disease prediction. source
- 2026-05-27 partnership Insilico Medicine and Human Longevity have partnered to build AI foundation models for disease prediction. source
- 2026-05-18 funding Eli Lilly acquired drug candidates from Insilico Medicine for $2.75 billion. source
- 2026-05-18 funding Eli Lilly acquired drug candidates from Insilico Medicine for $2.75 billion. source
- 2026-05-18 funding Eli Lilly acquired drug candidates from Insilico Medicine for $2.75 billion. source
9 day(s) with sentiment data
-
Discovered Materials raises $9M for AI-driven chip material discovery
Discovered Materials, a startup emerging from Y Combinator, has secured $9 million in seed funding to develop AI agents capable of discovering new materials for more efficient semiconductor chips. The company utilizes a…
-
Insilico Medicine uses AI to accelerate drug discovery, licensing platform to top pharma
Insilico Medicine is leveraging generative AI to significantly accelerate and reduce the cost of drug discovery. The company has successfully used its AI platform to design a drug candidate that advanced to phase 2 clin…
-
Generative biology uses AI to design drugs now in human trials
Generative biology, which uses AI to design molecules and biological functions, is transitioning from research to clinical application. Companies like Generate Biomedicines and Insilico Medicine are leveraging AI to cre…
-
MacPaw and Liquid AI partner for on-device AI on Macs
MacPaw and Liquid AI have formed a partnership to develop on-device AI capabilities for macOS. This collaboration will integrate Liquid AI's foundation models with MacPaw's Elix and Mnemos technologies to create a local…
-
AI News Roundup: Claude Opus 5 Benchmark, ChatGPT Adoption, and Regulatory Moves
Several AI developments are making headlines, including Anthropic's Claude Opus 5 achieving a new benchmark record on ARC-AGI-3. Meanwhile, OpenAI's ChatGPT is seeing widespread adoption by employees for tasks beyond th…
-
AI accelerates drug discovery, but data quality and lab bottlenecks remain challenges · 4 sources tracked
Artificial intelligence is accelerating drug discovery by enabling predictive design of drug candidates, which reduces the need for extensive physical screening. However, this speed highlights bottlenecks in laboratory …
-
Eli Lilly invests $2.75B in AI drug discovery firm Insilico Medicine
Eli Lilly and Company has acquired Insilico Medicine for $2.75 billion, highlighting a significant trend of major pharmaceutical companies investing heavily in AI-driven drug discovery. This single-week investment surge…
-
AI dramatically accelerates drug development, cutting costs and timelines by up to 70%
Artificial intelligence is significantly accelerating drug development, with a recent survey indicating that AI can reduce preclinical costs and timelines by up to 70%. This advancement is driving demand for sophisticat…
-
30 Entrepreneurs Share AI Development Expectations for China at WAIC 2026
Thirty entrepreneurs, including representatives from Zhipu AI and JD.com, have penned a letter outlining their expectations for China's artificial intelligence development ahead of the 2026 World AI Conference (WAIC). T…
-
AI in Pharma: Anthropic Launches Claude Science, Insilico Medicine Secures $600M Deal
AI is making significant strides in the pharmaceutical industry, moving beyond conceptual stages to deliver tangible value. Companies like Anthropic have launched specialized AI products for scientific research and drug…
-
AI accelerates drug discovery with major partnerships; China advances BCI tech
AI is making significant strides in drug discovery and development, moving beyond theoretical concepts to tangible value. Anthropic has launched Claude Science for pharmaceutical companies and initiated its own drug res…
-
Insilico Medicine advances AI-discovered drug rentosertib to Phase III trials for IPF
Insilico Medicine is moving its AI-discovered drug, rentosertib, into Phase III clinical trials for idiopathic pulmonary fibrosis (IPF). The drug, which targets the TNIK protein, showed promising results in Phase II tri…
-
Southbound Investors Increase Holdings in 16 Stocks, Yunzhisheng Leads Growth
A recent analysis of Southbound Stock Connect data reveals that 16 individual stocks experienced a week-over-week increase of over 10% in holdings by Southbound investors. Yunzhisheng led this trend with a 66.22% increa…
-
Anthropic launches Claude Science, plans to develop its own drugs
Anthropic has introduced Claude Science, a new research environment designed to accelerate scientific discovery by integrating tools, datasets, and visualization capabilities. Beyond providing AI tools for the life scie…
-
Takeda partners with Insilico Medicine for $600M AI drug discovery deal
Takeda Pharmaceutical Company has entered into a strategic collaboration with Insilico Medicine, utilizing AI for early-stage drug discovery. The deal, potentially worth up to US$600 million, grants Takeda exclusive wor…
-
Insilico Medicine and SK Biopharmaceuticals ink $2.5B AI drug discovery deal
Insilico Medicine and SK Biopharmaceuticals have entered into a significant research collaboration valued at over $2.5 billion. The partnership will leverage Insilico's AI-driven Pharma.AI platform to discover novel dru…
-
China's biotech industry expands globally despite US pressure
Chinese biotech firms are pushing for global expansion despite facing significant pressure and regulatory hurdles from the United States. These companies are increasingly turning to overseas licensing deals to access in…
-
Eli Lilly invests $2.75B in AI-designed drugs from Insilico Medicine
Eli Lilly and Company has acquired drugs designed by Insilico Medicine for $2.75 billion, highlighting the growing impact of AI in drug discovery. This significant investment is part of a larger trend, with Big Pharma c…
-
Insilico Medicine addresses Abu Dhabi secondary listing rumors
Insilico Medicine has addressed recent media reports suggesting a potential secondary listing in Abu Dhabi. While the company stated it continuously evaluates capital operations, including secondary listings, it current…
-
Insilico and Human Longevity partner on AI disease prediction models
Insilico Medicine and Human Longevity have formed a partnership to develop AI foundation models aimed at predicting diseases decades in advance. This collaboration combines Insilico's AI algorithms with Human Longevity'…